2001 Fiscal Year Final Research Report Summary
THE EFFECTS OF INHIBITORS OF OSTEOCLASTC BONE RESORPTION IN GIANT CELL TUMOR
| Project/Area Number |
11671443
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | OITA MEDICAL UNIVERSITY |
|---|
Principal Investigator |
YOSHIDA Seiji OITA MEDICAL UNIVERSITY, ORTHOPAEDICS, ASSISTANT, 医学部, 助手 (70182764)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATAOKA Masashi OITA MEDICAL UNIVERSITY, ORTHOPAEDICS, ASSISTANT, 医学部, 助手 (40301379)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Keywords | Giant cell tumor / Bisphosphonate / Estrogen / TRAP / TRAP |
|---|
| Research Abstract |
Bisphosphonates inhibit bone resorption and are therapeutically effective in diseases of increased bone turnover, such as Paget's disease and hypercalcemia of malignancy. The mechanisms by which they act remain unclear. Proposed mechanisms include inhibition of osteoclast formation from precursors and inhibitory or toxic effect on mature osteoclasts. We have developed a new in vitro model to study osteoclast survival and in this paper that may explain both the observed reduction in osteoclast numbers and in bone resorption by mature osteoclasts, namely that bisphosphonates induce programd cell death (apoptosis). Three bisphosphonates caused a 4- to 24-fold increase in the proportion of osteoclasts showing the characteristic morphology of apoptosis in vitro. Of the three compounds, risedronate, the most potent inhibitor of bone resorption in vivo, was the strongest inducer of osteoclast apoptosis in vitro. Osteoclast apoptosis may therefore be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.
|
